Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis

Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis

In inflammatory bowel disease, dysregulated T cells express pro-inflammatory cytokines. Using a chronic azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis model resembling ulcerative colitis, we evaluated whether and when treatment with the Janus kinase (JAK) inhibitor tofacitinib could...

Full description

Bibliographic Details
Main Authors: Rishav Seal, Lara S. U. Schwab, Cristina M. Chiarolla, Nadine Hundhausen, Georg Heinrich Klose, Simone Reu-Hofer, Andreas Rosenwald, Johannes Wiest, Friederike Berberich-Siebelt
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
anti-inflammatory cytokines
AOM/DSS
pro-inflammatory cytokines
effector Treg (eTreg)
chronic IBD model
JAK inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1179311/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1179311/full

Similar Items